Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 73

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Leptin alters energy intake and fat mass but not energy expenditure in lean subjects

Chrysafi, Pavlina, Perakakis, Nikolaos, Farr, Olivia M., Stefanakis, Konstantinos, Peradze, Natia, Sala-Vila, Aleix, Mantzoros, Christos S.·2020·Nature Communications
DOI 10.1038/s41467-020-18885-9
Open this paper in CoChat — free account

Abstract

Based on studies in mice, leptin was expected to decrease body weight in obese individuals. However, the majority of the obese are hyperleptinemic and do not respond to leptin treatment, suggesting the presence of leptin tolerance and questioning the role of leptin as regulator of energy balance in humans. We thus performed detailed novel measurements and analyses of samples and data from our clinical trials biobank to investigate leptin effects on mechanisms of weight regulation in lean normo- and mildly hypo-leptinemic individuals without genetic disorders. We demonstrate that short-term leptin administration alters food intake during refeeding after fasting, whereas long-term leptin treatment reduces fat mass and body weight, and transiently alters circulating free fatty acids in lean mildly hypoleptinemic individuals. Leptin levels before treatment initiation and leptin dose do not predict the observed weight loss in lean individuals suggesting a saturable effect of leptin. In contrast to data from animal studies, leptin treatment does not affect energy expenditure, lipid utilization, SNS activity, heart rate, blood pressure or lean body mass.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-18885-9

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 66

  1. Considine, R. V. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334, 292–295 (1996). · DOI · Paper page
  2. Boden, G., Chen, X., Mozzoli, M. & Ryan, I. Effect of fasting on serum leptin in normal human subjects. J. Clin. Endocrinol. Metab. 81, 3419–3423 (1996).
  3. Wu, B. et al. Effect of repeated fasting/refeeding on body weight control and energy balance regulation in rats. Wei Sheng Yan Jiu 39, 601–605 (2010).
  4. Audi, L. et al. Leptin in relation to resumption of menses in women with anorexia nervosa. Mol. Psychiatry 3, 544–547 (1998). · DOI
  5. Halaas, J. L. et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543–546 (1995). · DOI · Paper page
  6. Singh, A. et al. Leptin-mediated changes in hepatic mitochondrial metabolism, structure, and protein levels. Proc. Natl Acad. Sci. USA 106, 13100–13105 (2009). · DOI
  7. Halaas, J. L. et al. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc. Natl Acad. Sci. USA 94, 8878–8883 (1997). · DOI · Paper page
  8. Brown, R. J. et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine 60, 479–489 (2018). · DOI
  9. Farooqi, I. S. et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Investig. 110, 1093–1103 (2002). · DOI · Paper page
  10. Lee, J. H., Chan, J. L., Sourlas, E., Raptopoulos, V. & Mantzoros, C. S. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 91, 2605–2611 (2006). · DOI · Paper page
  11. Oral, E. A. et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine 64, 500–511 (2019). · DOI
  12. Heymsfield, S. B. et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J. Am. Med. Assoc. 282, 1568–1575 (1999). · DOI · Paper page
  13. Mittendorfer, B. et al. Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes 60, 1474–1477 (2011). · DOI
  14. Shetty, G. K. et al. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur. J. Endocrinol. 165, 249–254 (2011). · DOI
  15. Fogteloo, A. J., Pijl, H., Frolich, M., McCamish, M. & Meinders, A. E. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans. Diabetes, Nutr. Metab. 16, 109–114 (2003).
  16. Hukshorn, C. J. et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J. Clin. Endocrinol. Metab. 85, 4003–4009 (2000). · DOI · Paper page
  17. Hukshorn, C. J. et al. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int. J. Obes. Relat. Metab. Disord.: J. Int. Assoc. Study Obes. 26, 504–509 (2002). · DOI
  18. Lejeune, M. P., Hukshorn, C. J., Saris, W. H. & Westerterp-Plantenga, M. S. Effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB) treatment of overweight men. Int. J. Obes. Relat. Metab. Disord.: J. Int. Assoc. Study Obes. 27, 1494–1499 (2003). · DOI
  19. DePaoli, A., Long, A., Fine, G. M., Stewart, M. & O’Rahilly, S. Efficacy of metreleptin for weight loss in overweight and obese adults with low leptin levels. Diabetes 67, 296 (2018). · DOI
  20. Flier, J. S. & Maratos-Flier, E. Leptin’s physiologic role: does the emperor of energy balance have no clothes? Cell Metab. 26, 24–26 (2017). · DOI
  21. Chan, J. L., Heist, K., DePaoli, A. M., Veldhuis, J. D. & Mantzoros, C. S. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J. Clin. Investig. 111, 1409–1421 (2003). · DOI · Paper page
  22. Chan, J. L. et al. Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc. Natl Acad. Sci. USA 103, 8481–8486 (2006). · DOI · Paper page
  23. Chou, S. H. et al. Leptin is an effective treatment for hypothalamic amenorrhea. Proc. Natl Acad. Sci. USA 108, 6585–6590 (2011). · DOI · Paper page
  24. Chan, J. L., Wong, S. L. & Mantzoros, C. S. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin. Pharmacokinetics 47, 753–764 (2008). · DOI
  25. Mackowiak, P. A., Wasserman, S. S. & Levine, M. M. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. J. Am. Med. Assoc. 268, 1578–1580 (1992). · DOI · Paper page
  26. Gilgen-Ammann, R. et al. Energy expenditure estimation from respiration variables. Sci. Rep. 7, 15995 (2017). · DOI
  27. Steinhauser, M. L. et al. The circulating metabolome of human starvation. JCI insight 3, e121434 (2018). · DOI
  28. Perry, R. J. et al. Leptin mediates a glucose-fatty acid cycle to maintain glucose homeostasis in starvation. Cell 172, 234–248 (2018). · DOI
  29. Rosenbaum, M. & Leibel, R. L. Physiological responses to leptin levels in lipodystrophy: a model for other hypoleptinemias? J. Clin. Investig. 128, 3237–3239 (2018). · DOI
  30. Pelleymounter, M. A. et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269, 540–543 (1995). · DOI · Paper page
  31. Tang, G. B., Tang, X. F., Li, K. & Wang, D. H. Intracerebroventricular administration of leptin increase physical activity but has no effect on thermogenesis in cold-acclimated rats. Sci. Rep. 5, 11189 (2015). · DOI
  32. Pandit, R., Beerens, S. & Adan, R. A. H. Role of leptin in energy expenditure: the hypothalamic perspective. Am. J. Physiol. Regul. Integr. Comp. Physiol. 312, R938–R947 (2017). · DOI
  33. Correia, M. L., Morgan, D. A., Sivitz, W. I., Mark, A. L. & Haynes, W. G. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension 37, 936–942 (2001). · DOI
  34. Morton, G. J. et al. Identification of a physiological role for leptin in the regulation of ambulatory activity and wheel running in mice. Am. J. Physiol. Endocrinol. Metab. 300, E392–E401 (2011). · DOI
  35. Satoh, N. et al. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes 48, 1787–1793 (1999). · DOI
  36. Shibuya, I. et al. Regulation of catecholamine synthesis by leptin. Ann. N. Y Acad. Sci. 971, 522–527 (2002). · DOI
  37. Korner, J. et al. Randomized double-blind placebo-controlled study of leptin administration after gastric bypass. Obesity 21, 951–956 (2013). · DOI · Paper page
  38. Kissileff, H. R. et al. Leptin reverses declines in satiation in weight-reduced obese humans. Am. J. Clin. Nutr. 95, 309–317 (2012). · DOI
  39. Rosenbaum, M., Sy, M., Pavlovich, K., Leibel, R. L. & Hirsch, J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J. Clin. Investig. 118, 2583–2591 (2008).
  40. Ahima, R. S. et al. Role of leptin in the neuroendocrine response to fasting. Nature 382, 250–252 (1996). · DOI · Paper page
  41. Hwa, J. J. et al. Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice. Am. J. Physiol. 272, R1204–R1209 (1997).
  42. Lawler, K. et al. Leptin-mediated changes in the human metabolome. J. Clin. Endocrinol. Metab. 105, dgaa251 (2020). · DOI
  43. Grewal, S. et al. Metabolomic analysis of the effects of leptin replacement therapy in patients with lipodystrophy. J. Endocr. Soc. 4, bvz022 (2020). · DOI
  44. Clemmons, D. R. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol. Metab. Clin. North Am. 41, 425–443 (2012). · DOI · Paper page
  45. Kaklamani, V. G. et al. Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J. Clin. Oncol. 17, 3291–3298 (1999). · DOI
  46. Kirsten, R. et al. Effects of aldosterone on lipid metabolism and renal oxygen consumption in the rat. Pflug. Arch. 368, 189–194 (1977). · DOI
  47. Puschel, J. et al. Beneficial effects of leptin substitution on impaired eating behavior in lipodystrophy are sustained beyond 150 weeks of treatment. Cytokine 113, 400–404 (2019). · DOI
  48. Schlogl, H. et al. Leptin substitution in patients with lipodystrophy: neural correlates for long-term success in the normalization of eating behavior. Diabetes 65, 2179–2186 (2016). · DOI
  49. Farr, O. M. et al. Leptin therapy alters appetite and neural responses to food stimuli in brain areas of leptin-sensitive subjects without altering brain structure. J. Clin. Endocrinol. Metab. 99, E2529–E2538 (2014). · DOI
  50. Westerterp-Plantenga, M. S., Saris, W. H., Hukshorn, C. J. & Campfield, L. A. Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men. Am. J. Clin. Nutr. 74, 426–434 (2001). · DOI
  51. Chan, J. L., Mietus, J. E., Raciti, P. M., Goldberger, A. L. & Mantzoros, C. S. Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans. Clin. Endocrinol. 66, 49–57 (2007). · DOI · Paper page
  52. Ainsworth, B. E. et al. 2011 Compendium of physical activities: a second update of codes and MET values. Med. Sci. sports Exerc. 43, 1575–1581 (2011). · DOI · Paper page
  53. Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ. Cardiovasc. Genet. 8, 192–206 (2015). · DOI
  54. Soininen, P. et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 134, 1781–1785 (2009). · DOI · Paper page
  55. Inouye, M. et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol. Syst. Biol. 6, 441 (2010). · DOI
  56. Zuber, V., Colijn, J. M., Klaver, C. & Burgess, S. Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomization. Nat. Commun. 11, 29 (2020). · DOI
  57. Hagenbeek, F. A. et al. Heritability estimates for 361 blood metabolites across 40 genome-wide association studies. Nat. Commun. 11, 39 (2020). · DOI
  58. Vojinovic, D. et al. Relationship between gut microbiota and circulating metabolites in population-based cohorts. Nat. Commun. 10, 5813 (2019). · DOI
  59. Gallois, A. et al. A comprehensive study of metabolite genetics reveals strong pleiotropy and heterogeneity across time and context. Nat. Commun. 10, 4788 (2019). · DOI
  60. Deelen, J. et al. A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals. Nat. Commun. 10, 3346 (2019). · DOI · Paper page
  61. Holmes, M. V. et al. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J. Am. Coll. Cardiol. 71, 620–632 (2018). · DOI · Paper page
  62. Wurtz, P. & Soininen, P. Reply to: “Methodological issues regarding: “a third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals””. Atherosclerosis 302, 59–61 (2020). · DOI
  63. Liu, J. et al. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat. Med. 26, 110–117 (2020). · DOI
  64. Julkunen, H., Cichonska, A., Slagboom, P. E. & Würtz, P. Blood biomarker score identifies individuals at high risk for severe COVID-19 a decade prior to diagnosis: metabolic profiling of 105,000 adults in the UK Biobank. Preprint at https://doi.org/10.1101/2020.07.02.20143685 (2020). · DOI
  65. Agren, J. J., Julkunen, A. & Penttila, I. Rapid separation of serum lipids for fatty acid analysis by a single aminopropyl column. J. Lipid Res. 33, 1871–1876 (1992). · DOI
  66. Chong, J. & Xia, J. MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data. Bioinformatics 34, 4313–4314 (2018). · DOI · Paper page

Cited by

See all 73

Metadata

Authors
Chrysafi, P., Perakakis, N., Farr, O. M., Stefanakis, K., Peradze, N., Sala-Vila, A., & Mantzoros, C. S.
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2020-10-13
Volume
11
Issue
1
ISSN
2041-1723
DOI
10.1038/s41467-020-18885-9
Cited by
73
References
13
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.